Ask AI
ProCE Banner Activity

Elevating CLL/SLL Management to Align Community Practice With Clinical Guidelines, Evidence-Based Data, and Shared Decisions

Slideset

Explore the latest evidence and clinical guidelines for managing CLL/SLL, including novel treatment approaches for first line and beyond.

Released: April 20, 2026

Continue Activity

Share

Provided by

Provided by the National Comprehensive Cancer Network (NCCN) in collaboration with Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by educational grants from AstraZeneca and Lilly. 
This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA. 

AstraZeneca

Lilly

Merck & Co., Inc., Rahway, NJ, USA

Partners

Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Target Audience

This activity is intended for oncologists, hematologists, physician associates (PAs), nurse practitioners (NPs), nurses, pharmacists, and other healthcare professionals who care for patients with CLL/SLL.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Select first-line therapies for patients with treatment-naïve CLL/SLL considering available evidence, expert consensus and gui10670deline recommendations, toxicity profiles, prognostic variables, comorbidities, duration of treatment (continuous vs. fixed duration), and patient preferences

  • Establish individualized treatment plans for patients with relapsed/refractory CLL/SLL based on optimal sequencing strategies recommended in the NCCN Guidelines (eg, assessment of response/intolerance to first-line therapy, testing for resistant mutations, and patient eligibility for treatment)

  • Integrate newer therapeutic agents and regimens for the treatment of CLL/SLL in clinical practice in accordance with NCCN Guidelines and recent clinical trial data 

  • Employ shared decision-making (SDM) strategies in clinical practice to foster treatment adherence and persistence, and optimize care outcomes in patients with CLL/SLL